Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 0.76 |
| ▸ | CCNA2 | P20248 | 18/20 | 0.76 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.64 |
| ▸ | CDK4 | P11802 | 2/20 | 0.63 |
| ▸ | CCND1 | P24385 | 2/20 | 0.63 |
| ▸ | CDK9 | P50750 | 2/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.63 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.63 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.63 |
| ▸ | CCNK | O75909 | 1/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 1/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.62 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.62 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697935 | 0.93 | CCNA2 (0.69) | CDK2CCNA2CCNE1CDK4CCND1 | |
| SCHEMBL6191533 | 0.91 | CCNA2 (0.63) | CDK2CCNA2CCNE1CDK4CCND1 | |
| SCHEMBL5725380 | 0.91 | CCNA2 (0.67) | CDK2CCNA2CCNE1CDK4CCND1 | |
| SCHEMBL6694011 | 0.90 | CCNT1 (0.64) | CDK2CCNA2CDK4CCND1CDK9 | |
| SCHEMBL5725445 | 0.90 | CCNA2 (0.71) | CDK2CCNA2CCNE1CDK4CCND1 | |
| SCHEMBL6194773 | 0.90 | CCNA2 (0.70) | CDK2CCNA2CCNE1CDK4CCND1 | |
| SCHEMBL6194817 | 0.89 | CCNA2 (0.67) | CDK2CCNA2CDK4CCND1CDK9 | |
| SCHEMBL5725714 | 0.88 | CCNT1 (0.62) | CDK2CCNA2CDK4CCND1CDK9 | |
| SCHEMBL6193752 | 0.88 | CCNA2 (0.67) | CDK2CCNA2CCNE1CDK4CCND1 | |
| SCHEMBL6193409 | 0.88 | CCNA2 (0.67) | CDK2CCNA2CCNE1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596631-B2 | CDK12 inhibitors and their uses | THE UNIVERSITY OF NOTTINGHAM (GB) | 2023-03-07 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20190038625-A1 | INHIBITORS AND THEIR USES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2019-02-07 | — | — | US | disclosed |
| WO-2017163076-A1 | INHIBITORS AND THEIR USES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2017-09-28 | — | — | WO | disclosed |
| EP-1364212-B1 | THREE HYBRID ASSAY SYSTEM | GPC BIOTECH AG (DE) | 2011-02-02 | — | — | EP | disclosed |
| EP-1215208-B1 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | AGOURON PHARMA (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1056732-B1 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMA (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CHONG WESLEY K M (US) | 2003-11-27 | — | — | US | disclosed |
| US-6569878-B1 | Such as 4-amino-2-phenylamino-thiazol-5-yl)-(3-nitrophenyl)-methanone for treating cancer | AGOURON PHARMACEUTICALS INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1215208-A2 | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases | Agouron Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| EP-1056732-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999021845-A2 | 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596631-B2 | CDK12 inhibitors and their uses | CDK12, CDK1, CDK17 | CDK2 13/4885CCNA2 16/4885CCNE1 59/4885 |
| US-20190038625-A1 | INHIBITORS AND THEIR USES | CDK12, CDK1, CDK17 | CDK2 12/4885CCNA2 14/4885CCNE1 56/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | CDK2 170/4885CCNA2 107/4885CCNE1 104/4885 |
| US-20030220326-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases | CDK2, CDK4, CDK1 | CDK2 1/4885CCNA2 24/4885CCNE1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.